Why is a small molecule of the RAGE pathway, an oral drug with long-term human safety accumulation, worth the attention of Chinese pharmaceutical companies? — Core judgment of
Recently, the biopharmaceutical industry has seen multiple developments: Quan Zhen Tong has released the “Quan Diagnosis 5.0” clinical AI intelligent partner; The approved protection rate of
In biopatent practice, “serial identity” is a frequent pain point during the drafting and examination response stages of claims. Broad identities are prone to scrutiny that
On July 30, the National Intellectual Property Administration issued Decision No. 588094 invalidation request, upholding the validity of the invention patent right for “a pharmaceutical composition and
uploads a photo of yourself, then records a voice message, and a digital version of “you” that blinks, opens your mouth, and has a natural expression
For a long time, pharmaceutical companies’ understanding of intellectual property remained at the legal level—R&D teams completed molecular screening, clinical trials, and application materials, and only
Starting August 1, the China-Europe Patent Examination Expressway (PPH) pilot, jointly launched by the China National Intellectual Property Administration and the European Patent Office (EPO), as well
Introduction: From research and development to market launch, innovative drugs require a long cycle and significant investment, and their commercial value heavily depends on intellectual property
Introduction On August 5, the China Intellectual Property Research Association, together with 13 overseas guiding council member units including the Commercial Legal Service Center of the
This week, financing news in the biopharmaceutical sector has arrived: eight innovative companies, including Huode Biotech, Deep Cell, and Zhongke Aoge, have successively secured financing ranging